Literature DB >> 12651012

Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives.

An Willems1, Jannick Leoen, Steve Schoonooghe, Johan Grooten, Nico Mertens.   

Abstract

Antibody fragments offer the possibility to build multifunctional manifolds tailored to meet a large variety of needs. We optimized the production of a manifold consisting of one (bibody) or two (tribody) single-chain variable fragments coupled to the C-terminus of Fab chains. Different strong mammalian promoters were compared and the influence of expression media on production and recovery was investigated. Since the physical and chemical nature of these molecules largely depends on the nature of the antibody building blocks incorporated, a generally applicable process for the purification of recombinant antibody derivatives from serum containing mammalian cell culture medium was designed. To this end we compared protein L, hydroxyapatite, immobilized metal affinity chromatography, cation-exchange chromatography and hydrophobic charge induction chromatography.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651012     DOI: 10.1016/s1570-0232(02)00813-9

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.

Authors:  Chen Chen; Tetsuya Wakabayashi; Masaru Muraoka; Feng Shu; Chia Wei Shan; Chong Chor Kun; Ching Tim Jang; Ishin Soehano; Yuichiro Shimizu; Tomoyuki Igawa; Jun-Ichi Nezu
Journal:  MAbs       Date:  2019-03-21       Impact factor: 5.857

2.  Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris.

Authors:  Steve Schoonooghe; Vladimir Kaigorodov; Monika Zawisza; Caroline Dumolyn; Jurgen Haustraete; Johan Grooten; Nico Mertens
Journal:  BMC Biotechnol       Date:  2009-08-11       Impact factor: 2.563

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.